tezepelumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 5500 1572943-04-4

Description:

MoleculeDescription

Molfile

Synonyms:

  • tezepelumab
  • tezepelumab-ekko
  • tezspire
  • MEDI19929
  • AMG 157
Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2lambda that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in the asthma inflammatory cascade. Airway inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in airway inflammation. Blocking TSLP with tezepelumab-ekko reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has not been definitively established.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2022 EMA ASTRAZENECA AB
Dec. 17, 2021 FDA ASTRAZENECA AB
Sept. 26, 2022 PMDA ASTRAZENECA K.K

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arthralgia 54.52 41.58 50 766 569660 62918546
Anaphylactic reaction 47.46 41.58 21 795 66079 63422127

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Arthralgia 59.12 40.56 41 525 571762 79172060

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03DX11 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Other systemic drugs for obstructive airway diseases
FDA EPC N0000194010 Thymic Stromal Lymphopoietin Blocker
FDA MoA N0000194011 Thymic Stromal Lymphopoietin Blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Severe asthma indication 370221004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thymic stromal lymphopoietin Cytokine BLOCKER 10.80 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL3707229 ChEMBL_ID
C000622721 MESH_SUPPLEMENTAL_RECORD_UI
8933 IUPHAR_LIGAND_ID
DB15090 DRUGBANK_ID
018915 NDDF
4041094 VANDF
4041095 VANDF
D11771 KEGG_DRUG
C4550163 UMLSCUI
CHEMBL2109595 ChEMBL_ID
10172 INN_ID
2587789 RXNORM
354400 MMSL
40182 MMSL
d09841 MMSL
RJ1IW3B4QX UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-100 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-100 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-100 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-112 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-112 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-112 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections
TEZSPIRE HUMAN PRESCRIPTION DRUG LABEL 1 55513-123 INJECTION, SOLUTION 210 mg SUBCUTANEOUS BLA 28 sections